-Lead R&D activities -Conduct business development -Manage projects and communicate with clients-Generate quotations

-Established direct connections with CROs and academic collaborators, ensuring effective project management and communication.-Assisted CROs in complex problem solving on techniques and logistics-Collaborated with team leaders and executives to develop and execute project plans.-Provided advanced alerts on upcoming milestones, facilitating goal achievement.-Assisted in goal setting and resource allocation, identified program risks, and managed budgets.-Created and maintained project progress trackers and dashboards.-Engaged with key stakeholders to ensure timely project deliverables.-Supported project partnerships and business development activities.-Worked with the legal department on CDA, MSA, and SOW negotiations.-Designed novel oligonucleotides and mentored junior scientists on new amidites synthesis.

-Designed and synthesized taste modulators, demonstrating strong SAR expertise.-Discovered and developed commercial routes for novel taste enhancers.-Synthesized natural ingredients and transferred to manufacturing facilities.-Supported patent applications to protect company’s intellectual property.

- Contributed to various therapeutic areas, including CNS, cardiovascular, and metabolic diseases.- Developed robust synthetic routes through multiple-step synthesis.- Managed external FTEs at CROs, streamlining collaborations and project execution.- Accomplished a 2 month secondment at Wuxi AppTec to streamline the cooperations.- Supervised an intern in method development of a novel heterocycle synthesis.

-Made significant contributions to oncology and anticancer drug discovery projects.-Recognized for problem-solving and accelerated synthesis for the team.-Selected to participate in an internal workshop designed exclusively for highly skilled scientists, showcasing strong interpersonal and leadership skills.

-Made major contribution to the discovery of Adomeglivant (LY2409021), a Glucagon Antagonist that underwent Phase -2 clinical trials for the treatment of diabetes.-Made conceptions which led to the new key scaffolds and SAR breakthroughs.-In 2004, synthesized >300 medicinal chemistry analogs, representing 33% of the team (11 FTEs).-In 2004, contributed 23 compounds for in-vivo study, accounting for ~50% of the team.-Nominated by the senior management to participate in an internal workshop designed exclusively for highly skilled scientists

-Focused on anti-infectives and the discovery of bacterial translation inhibitors.-Synthesized and purification of analogs by Flash Column Chromatography.-Conducted SAR study and biological data analysis.-Consistently rated in the top 10% or higher for performance.